The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.
NACompletedINTERVENTIONAL
Enrollment
66
Participants
Timeline
Start Date
February 28, 2014
Primary Completion Date
March 31, 2014
Study Completion Date
April 30, 2015
Conditions
Diabetes Mellitus
Interventions
DRUG
Vildagliptin 50 MG
50 mg Vildagliptin as single-dose per study period
All Listed Sponsors
lead
AET Laboratories Private Limited
INDUSTRY
NCT05329844 - The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed. | Biotech Hunter | Biotech Hunter